Skip to main content

Health condition · Clinically reviewed

DSRCT, a rare, aggressive sarcoma that belongs in a specialist centre.

Desmoplastic small round cell tumour is an EWSR1-WT1 driven soft-tissue sarcoma of the abdomen. It is rare, it hits adolescents and young adults, and it is treated by supra-regional UK teams with a multimodal plan.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, NHS specialist commissioning, Sarcoma UK and peer-reviewed sarcoma literature.

  • 03

    Current for 2026

    Reflects modern UK practice across supra-regional sarcoma centres, peritoneal surface malignancy units and AYA oncology services.

Key facts

DSRCT at a glance.

The essentials, in plain English - what DSRCT is, who it affects, and how it is treated in UK specialist centres today.

  • What it is

    A very rare, highly aggressive soft-tissue sarcoma - desmoplastic small round cell tumour, mostly seated on the peritoneum and omentum of the abdomen.

  • Who it affects

    Predominantly adolescents and young adults aged 15 to 30. Roughly four times more common in males than females.

  • How rare

    Incidence is around 1 in 1,000,000 - a supra-regional referral condition, not a district general one.

  • Molecular signature

    Defined by the EWSR1-WT1 fusion gene from the t(11;22)(p13;q12) translocation - pathognomonic on FISH or RT-PCR.

  • Presentation

    Often advanced at diagnosis - abdominal pain, distension, a palpable mass, ascites and weight loss. Peritoneal, liver, lung and nodal disease are common.

  • Treatment shape

    Multimodal - intensive chemotherapy, aggressive cytoreductive surgery (sometimes with HIPEC), radiotherapy and clinical trials, all in a specialist centre.

Why this guide matters

Rare, aggressive, treatable in expert hands.

Three ideas shape everything else on this page - the diagnosis is molecular, the plan is multimodal, and the centre matters as much as the drugs.

  • The diagnosis is molecular

    Small round blue cells and desmoplastic stroma point at DSRCT. The EWSR1-WT1 fusion nails it - and rules out its mimics.

  • Treatment is multimodal

    Intensive chemotherapy, aggressive cytoreductive surgery (often with HIPEC) and radiotherapy are the backbone - not any one of them alone.

  • The centre matters

    Supra-regional sarcoma and peritoneal surface malignancy centres do this every year. District-general oncology does not.

How the diagnosis is made

From vague symptoms to a molecular diagnosis.

The steps a UK sarcoma team follows in order - so you know what to expect, why each test is done and where a specialist referral fits.

  1. 01

    Assessing

    Symptom review and examination

    A careful history of abdominal pain, distension, weight loss and fatigue - with an abdominal exam looking for a mass, ascites and organomegaly.

  2. 02

    Assessing

    Cross-sectional imaging

    Contrast CT of chest, abdomen and pelvis is the workhorse - showing peritoneal deposits, omental caking, ascites and organ involvement.

  3. 03

    Assessing

    PET-CT and MRI

    FDG PET-CT maps active disease and distant spread. MRI adds soft-tissue detail for pelvic and hepatic disease.

  4. 04

    Confirming

    Specialist sarcoma biopsy

    Image-guided or laparoscopic biopsy in a sarcoma centre - histology shows small round blue cells set in a dense desmoplastic stroma.

  5. 05

    Confirming

    Immunohistochemistry

    A polyphenotypic pattern - keratin, desmin (dot-like), WT1, vimentin and neuron-specific enolase - separates DSRCT from other small round cell tumours.

  6. 06

    Confirming

    Molecular confirmation

    FISH or RT-PCR for the EWSR1-WT1 fusion is the defining test. Its presence confirms the diagnosis and its absence prompts a rethink.

  7. 07

    Preparing

    Supra-regional MDT

    Onward review at a specialist sarcoma MDT - Royal Marsden, Christie, UCLH, Bristol, Newcastle, Cambridge, Leeds, Manchester, Nottingham, Oxford or Sheffield - to plan multimodal therapy.

Typical timeline: from first scan to a specialist MDT plan in weeks, not months.

Symptoms

What DSRCT looks like in practice.

The features that bring people to see a doctor - and the ones that mark advanced or metastatic disease.

  • Abdominal pain

    Often the first symptom - a dull ache or dragging discomfort that gradually worsens as peritoneal deposits enlarge.

  • Abdominal distension

    From bulky peritoneal disease, omental caking and ascites - trousers and belts feel tighter over weeks to months.

  • Palpable abdominal mass

    A firm, often fixed mass in the pelvis or upper abdomen - sometimes the trigger for the first scan.

  • Ascites

    Fluid accumulation causing distension, early satiety and shortness of breath - a common late feature.

  • Weight loss and fatigue

    Unintentional weight loss, poor appetite and profound tiredness - typical of advanced intra-abdominal disease.

  • Bowel and urinary change

    Pelvic disease can compress bowel or bladder, causing altered habit, obstruction or urinary symptoms.

  • Metastatic features

    Liver, lung and lymph-node disease at diagnosis are common - jaundice, cough or nodal masses may be the presenting complaint.

  • Red flag - delayed diagnosis

    Non-specific symptoms in a young adult mean DSRCT is often advanced by the time it is found - persistent, unexplained abdominal symptoms deserve imaging.

Treatment

How DSRCT is treated in the UK.

There is no single standard-of-care protocol. Care is stitched together from intensive chemotherapy, radical surgery with HIPEC, radiotherapy and clinical trials - always in a specialist centre.

  • Modified P6 chemotherapy

    The Memorial Sloan Kettering P6 regimen alternates high-dose cyclophosphamide, doxorubicin and vincristine with ifosfamide and etoposide - typically five to seven cycles as neoadjuvant induction.

  • VDC/IE chemotherapy

    An Ewing-sarcoma-like alternative - vincristine, doxorubicin and cyclophosphamide alternating with ifosfamide and etoposide - used when P6 is not appropriate.

  • Cytoreductive surgery

    Aggressive debulking with peritonectomy and multi-visceral resection at a specialist peritoneal surface malignancy centre - Basingstoke, Christie or the Beatson.

  • HIPEC

    Hyperthermic intraperitoneal chemotherapy delivered at the time of surgery in selected patients - to treat microscopic residual peritoneal disease.

  • Whole abdominopelvic radiotherapy

    Consolidative radiotherapy to the whole abdomen and pelvis, with boosts to residual disease - a specialist technique with careful bowel and marrow dose planning.

  • High-dose chemo and stem-cell rescue

    Autologous stem-cell rescue after high-dose chemotherapy has been used historically. Evidence is variable and it is reserved for specialist protocols.

  • Targeted and second-line therapy

    Pazopanib, sunitinib, trabectedin, eribulin, regorafenib and irinotecan-temozolomide are all options in relapsed or refractory disease.

  • Clinical trials

    CAR-T cell therapies against B7-H3 or GD2, anti-IGF-1R agents and PARP inhibitors are all in trial - the Royal Marsden, UCL and specialist paediatric units are natural referral points.

What this guide is based on

The sources behind every claim on this page.

UK national commissioning guidance, sarcoma society standards and specialist centre protocols, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your sarcoma team knows the details of your disease and can tell you which parts of this apply to you. When in doubt, ring your clinical nurse specialist.

  • NHS England. Specialised sarcoma services and peritoneal surface malignancy service specifications.

  • NICE. Sarcoma: quality standard (QS78) and improving outcomes for people with sarcoma.

  • European Society for Medical Oncology (ESMO). Soft-tissue and visceral sarcomas: clinical practice guidelines.

  • Sarcoma UK. Patient information on rare sarcomas including DSRCT.

  • Memorial Sloan Kettering. Published DSRCT protocols (P6 and successors) and long-term outcome data.

Red flags

When DSRCT needs urgent attention.

These are the situations that shouldn’t wait for a routine appointment - they need a same-day call to the acute oncology line or A&E.

  • Bowel obstruction

    Vomiting, absolute constipation and distension in known peritoneal disease - a surgical emergency needing prompt hospital review.

  • Rapidly enlarging ascites

    Sudden abdominal swelling with breathlessness - drain in a specialist setting and reassess disease control.

  • Uncontrolled pain

    Escalating abdominal or pelvic pain despite standard analgesia - warrants urgent specialist palliative-care input.

  • Neutropenic sepsis

    Fever, rigors or unwellness on chemotherapy - a medical emergency needing same-hour antibiotics under the sarcoma or oncology team.

  • Spinal cord compression

    New back pain with leg weakness, numbness or bladder change in metastatic disease - an emergency needing MRI within 24 hours.

  • Venous thromboembolism

    Unilateral leg swelling, chest pain or breathlessness - DSRCT and its treatments raise clotting risk and thresholds for imaging should be low.

  • Jaundice or hepatic failure

    New jaundice, confusion or itch - suggests progressive hepatic disease or biliary obstruction and needs urgent specialist review.

  • Psychological crisis

    DSRCT hits adolescents and young adults hard. Suicidal thoughts, severe distress or crisis deserve urgent AYA psychology or Teenage Cancer Trust involvement.

  • Missed follow-up scans

    Given how quickly DSRCT can move, missed surveillance imaging deserves an urgent catch-up rather than a routine slot.

Living with it

A rare cancer, held by a specialist team.

Four ideas make daily life with DSRCT more workable - the right centre, the right support, an open door to trials and honest pacing.

A quiet reminder

You can ask for palliative care alongside active treatment.

Specialist palliative care is not the end of treatment. Introduced early, it protects quality of life and helps the sarcoma team give aggressive care safely.

  1. 01 Centre

    Stay tethered to a specialist unit

    DSRCT care is supra-regional. Being registered at a specialist sarcoma centre - with a named clinical nurse specialist - matters more than proximity.

  2. 02 Support

    Use AYA and charity support

    Sarcoma UK, Teenage Cancer Trust, CLIC Sargent (Young Lives vs Cancer), Macmillan and Cancer Research UK all offer age-appropriate practical, financial and emotional help.

  3. 03 Trials

    Ask about trials early

    Because there is no single standard-of-care protocol, clinical trials - including CAR-T and targeted therapy studies - are often the best next step. Ask, and ask again.

  4. 04 Living

    Plan life around cycles

    Intensive regimens are exhausting. Pace study, work, relationships and rest around treatment cycles rather than fighting them.

Frequently asked

Everything we get asked about DSRCT.

Quick answers on the diagnosis, treatment, outlook and where care happens in the UK.

  • What is DSRCT?

    Desmoplastic small round cell tumour is a very rare, highly aggressive soft-tissue sarcoma that mostly grows on the peritoneal surfaces and omentum inside the abdomen. It is defined by the EWSR1-WT1 fusion gene from a t(11;22)(p13;q12) translocation and predominantly affects adolescents and young adults, with males affected around four times more often than females.

  • Why is DSRCT often diagnosed late?

    The early symptoms are vague - dull abdominal pain, mild distension, fatigue and weight loss - and can look like far more common problems. By the time imaging is done, disease is often widespread on the peritoneum with liver, lung or nodal spread. Persistent, unexplained abdominal symptoms in a young adult deserve a scan rather than a wait-and-see.

  • How is the diagnosis confirmed?

    The gold standard is a specialist sarcoma pathology review of a biopsy - showing small round blue cells in a desmoplastic stroma, a polyphenotypic immunohistochemistry pattern (keratin, desmin, WT1, vimentin, neuron-specific enolase) and confirmation of the EWSR1-WT1 fusion on FISH or RT-PCR. Staging uses CT of the chest, abdomen and pelvis, PET-CT, MRI and often laparoscopy to map peritoneal disease.

  • What does treatment involve?

    DSRCT is treated in a supra-regional sarcoma centre with a multimodal plan - intensive chemotherapy (typically the modified P6 regimen or a VDC/IE alternative), aggressive cytoreductive surgery sometimes with HIPEC at a peritoneal surface malignancy unit, whole abdominopelvic radiotherapy and, in some cases, high-dose chemotherapy with stem-cell rescue. Targeted agents, immunotherapy and CAR-T are increasingly explored in clinical trials.

  • Is DSRCT hereditary?

    No. DSRCT is a sporadic tumour driven by a somatic EWSR1-WT1 fusion. It is not inherited and familial clusters are exceptionally rare. Genetic counselling is still often offered as part of comprehensive AYA sarcoma care and to help families understand risk more broadly.

  • What is the outlook?

    DSRCT remains one of the most aggressive sarcomas. Even with intensive multimodal therapy, five-year survival is under 20 per cent and relapse is common. That reality drives the emphasis on specialist centres, clinical trials, early palliative care alongside active treatment, and strong AYA psychological support throughout the journey.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.